Microbiome Diagnostics Market by Product (Kits & Reagents, Instruments), Technology (16s rRNA Sequencing, Shot Gun Metagenomics, Metatranscriptomics), Sample (Fecal, Saliva, Skin), Application (GI, Metabolic Disorders) - Global Forecast to 2028
The global microbiome diagnostics market is valued at an estimated USD 146 million in 2023 and is projected to reach USD 300 million by 2028, at a CAGR of 15.5% during the forecast period. Market growth is driven by factors such as increasing awareness of microbiome diagnostics, increasing demand of personalize medicine and increasing incidences of diseases.
“The reagents & kits to register the largest share of the microbiome diagnostics market, by product.”
The global microbiome diagnostics market is segmented into reagents & kits and instruments on product. Market growth is largely driven by the repetitive use of reagents & kits for microbiome-based diagnostic procedures coupled with the increase in the volume of microbiome-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.
“16s rRNA sequencing segment to grow at a considerable rate among technology during the forecast period.”
The microbiome diagnostics market is segmented into 16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technologies. As compared to capillary sequencing or PCR-based approaches, 16S rRNA sequencing is a culture-free technique that enables researchers to analyze the entire microbial community within a sample. Due to its ability to combine many samples in a sequencing run, NGS-based 16S rRNA sequencing is a cost-effective technique for identifying bacterial strains that may not be found using traditional methods.
“Research application segment accounted for the largest share in the microbiome diagnostics market, by application.”
The global microbiome diagnostics market is segmented into research application, disease diagnostic application. The application segment of disease diagnostic application accounted for a considerable share in 2022, primarily due to rising prevalence of diseases.
“Asia Pacific: The fastest-growing region in the microbiome diagnostics market.”
The global microbiome diagnostics market is segmented into five regions - North America, Europe, the Asia Pacific, Rest of the World. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the microbiome-based diagnostics market. The high growth in the region is due to the increasing incidences of diseases, increasing microbiome research activities in Asian countries.
The break-up of the profile of primary participants in the microbiome diagnostics market:
Research Coverage:
This research report categorizes the microbiome diagnostics market by product (reagents & kits and instruments), sample (feces, saliva, skin and other sample), technology (16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technology), application (research application, disease diagnosis and monitoring), end user (research institutes, pharmaceutical and biotechnology companies, hospitals and other end user), and region (North America, Europe, Asia Pacific, Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, opportunities, and challenges, influencing the growth of the microbiome diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the microbiome diagnostics market. This report covers the competitive analysis of upcoming startups in the microbiome-based diagnostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall microbiome diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
“The reagents & kits to register the largest share of the microbiome diagnostics market, by product.”
The global microbiome diagnostics market is segmented into reagents & kits and instruments on product. Market growth is largely driven by the repetitive use of reagents & kits for microbiome-based diagnostic procedures coupled with the increase in the volume of microbiome-based tests conducted worldwide. Moreover, the availability of better reagents & kits that offer efficient results and precision in diagnosis attributes to their growing requirement resulting in growth of the segment.
“16s rRNA sequencing segment to grow at a considerable rate among technology during the forecast period.”
The microbiome diagnostics market is segmented into 16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technologies. As compared to capillary sequencing or PCR-based approaches, 16S rRNA sequencing is a culture-free technique that enables researchers to analyze the entire microbial community within a sample. Due to its ability to combine many samples in a sequencing run, NGS-based 16S rRNA sequencing is a cost-effective technique for identifying bacterial strains that may not be found using traditional methods.
“Research application segment accounted for the largest share in the microbiome diagnostics market, by application.”
The global microbiome diagnostics market is segmented into research application, disease diagnostic application. The application segment of disease diagnostic application accounted for a considerable share in 2022, primarily due to rising prevalence of diseases.
“Asia Pacific: The fastest-growing region in the microbiome diagnostics market.”
The global microbiome diagnostics market is segmented into five regions - North America, Europe, the Asia Pacific, Rest of the World. The Asia Pacific region is expected to grow at the highest rate during the forecast period in the microbiome-based diagnostics market. The high growth in the region is due to the increasing incidences of diseases, increasing microbiome research activities in Asian countries.
The break-up of the profile of primary participants in the microbiome diagnostics market:
- By Company Type: Tier 1 - 55%, Tier 2 - 40%, and Tier 3 – 5%
- By Designation: C-level - 37%, D-level - 48%, and Others - 15%
- By Region: North America - 56%, Europe - 20%, Asia Pacific - 17%, Rest of the World– 7%,
Research Coverage:
This research report categorizes the microbiome diagnostics market by product (reagents & kits and instruments), sample (feces, saliva, skin and other sample), technology (16s rRNA sequencing, shotgun metagenomics, metatranscriptomics and other technology), application (research application, disease diagnosis and monitoring), end user (research institutes, pharmaceutical and biotechnology companies, hospitals and other end user), and region (North America, Europe, Asia Pacific, Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, opportunities, and challenges, influencing the growth of the microbiome diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the microbiome diagnostics market. This report covers the competitive analysis of upcoming startups in the microbiome-based diagnostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall microbiome diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
- Analysis of key drivers (The collaborative efforts between the microbiome industry and academia for microbiome research and the growing demand for personalized medicine, growing awareness about the importance of the human microbiome diagnostics, rising incidences of disease), opportunities (Increased collaboration of key players and small innovative companies to work on new microbiome technologies), and challenges (Adverse impact of complex regulatory policies on commercialization of microbiome ) influencing the growth of the microbiome-based market
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the microbiome diagnostics market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the microbiome diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the microbiome diagnostics market
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like DNA Genotek (Canada), Invivo Healthcare (UK), Microba Life Sciences (US), and Genetic Analysis AS (Norway)among others in the microbiome-based diagnostics market strategies.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
FIGURE 1 MICROBIOME-BASED DIAGNOSTICS MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 MICROBIOME-BASED DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
2.1.2.3 Breakdown of primary interviews
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary research
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 8 MICROBIOME-BASED DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 STUDY ASSUMPTIONS
2.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: MICROBIOME-BASED DIAGNOSTICS MARKET
2.6 IMPACT OF RECESSION ON MICROBIOME-BASED DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MICROBIOME-BASED DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 MICROBIOME-BASED DIAGNOSTICS MARKET OVERVIEW
FIGURE 16 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)
FIGURE 17 KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 18 CHINA AND INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHIC MIX
FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 MICROBIOME-BASED DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MICROBIOME-BASED DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of chronic diseases
FIGURE 22 GLOBAL INCIDENCE OF DIABETES, 2021 VS. 2045
5.2.1.2 Collaborative efforts between microbiome industry and academia for microbiome research
5.2.1.3 Growing demand for personalized medicine
5.2.1.4 Rising awareness about importance of human microbiomes
5.2.1.5 Rising funding and investments in microbiome research
5.2.2 RESTRAINTS
5.2.2.1 End-user budget constraints in developing countries
5.2.3 OPPORTUNITIES
5.2.3.1 Increased collaboration between key players and small innovative companies to work on new microbiome technologies
TABLE 3 COLLABORATIONS IN MICROBIOME-BASED DIAGNOSTICS MARKET
5.2.4 CHALLENGES
5.2.4.1 Adverse impact of complex regulatory policies on commercialization of microbiome
5.3 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 INTENSITY OF COMPETITIVE RIVALRY
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 THREAT OF SUBSTITUTES
5.6 KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 2 END USERS
5.6.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS
5.7 REGULATORY LANDSCAPE
5.7.1 NORTH AMERICA
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 EUROPE
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.3 ASIA PACIFIC
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.4 REST OF THE WORLD
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 ECOSYSTEM ANALYSIS
TABLE 8 ROLE IN ECOSYSTEM
FIGURE 27 KEY PLAYERS OPERATING IN MICROBIOME-BASED DIAGNOSTICS MARKET
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES & EVENTS
TABLE 9 LIST OF CONFERENCES & EVENTS IN 2023–2024
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
TABLE 10 PRICE RANGE OF PRODUCTS OFFERED BY KEY PLAYERS FOR APPLICATIONS (USD)
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 TECHNOLOGY ANALYSIS
5.13.1 DEVELOPMENT OF NOVEL MICROBIOME SAMPLING DEVICES
5.14 TRADE ANALYSIS
TABLE 11 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
6 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 KITS & REAGENTS
6.2.1 KITS & REAGENTS TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
TABLE 14 MICROBIOME-BASED DIAGNOSTIC KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING VOLUME OF BLOOD COLLECTION PROCEDURES TO DRIVE MARKET GROWTH
TABLE 15 MICROBIOME-BASED DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
7 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 16 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 16S RRNA SEQUENCING
7.2.1 ABILITY TO COMBINE MANY SAMPLES IN SEQUENCING RUN TO DRIVE DEMAND FOR NGS-BASED 16S RRNA SEQUENCING
TABLE 17 MICROBIOME-BASED DIAGNOSTICS MARKET FOR 16S RRNA SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
7.3 SHOTGUN METAGENOMICS
7.3.1 ABILITY OF SHOTGUN METAGENOMICS TO PROVIDE DETAILED GENETIC INFORMATION TO BOOST DEMAND
TABLE 18 COMPARISON BETWEEN SHOTGUN METAGENOMICS AND 16S RRNA SEQUENCING
TABLE 19 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SHOTGUN METAGENOMICS, BY REGION, 2021–2028 (USD MILLION)
7.4 METATRANSCRIPTOMICS
7.4.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING INSTRUMENTS TO DRIVE GROWTH
TABLE 20 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METATRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION)
7.5 OTHER TECHNOLOGIES
TABLE 21 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE
8.1 INTRODUCTION
TABLE 22 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
8.2 FECAL SAMPLES
8.2.1 FECAL SAMPLES TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
TABLE 23 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR FECAL SAMPLES
TABLE 24 MICROBIOME-BASED DIAGNOSTICS MARKET FOR FECAL SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.3 SALIVA SAMPLES
8.3.1 ADVANCEMENTS IN ORAL DIAGNOSTICS TO DRIVE MARKET GROWTH
TABLE 25 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SALIVA SAMPLES
TABLE 26 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SALIVA SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.4 SKIN SAMPLES
8.4.1 GROWING FOCUS ON MICROBIOME RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 27 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SKIN SAMPLES
TABLE 28 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SKIN SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SAMPLES
TABLE 29 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR OTHER SAMPLES
TABLE 30 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION)
9 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 31 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 DISEASE DIAGNOSTIC APPLICATIONS
TABLE 32 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 33 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9.2.1 GASTROINTESTINAL DISORDERS
9.2.1.1 Growing incidence of gastrointestinal disorders to drive market growth
TABLE 34 MICROBIOME-BASED DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.2.2 METABOLIC DISORDERS
9.2.2.1 High prevalence of metabolic disorders to drive demand for microbiome-based diagnostic products
TABLE 35 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.2.3 OTHER DISEASE DIAGNOSTIC APPLICATIONS
TABLE 36 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9.3 RESEARCH APPLICATIONS
9.3.1 GROWING RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 37 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 38 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS
10.2.1 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF MICROBIOME-BASED DIAGNOSTICS MARKET IN 2022
TABLE 39 MICROBIOME-BASED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
10.3 RESEARCH INSTITUTES
10.3.1 GROWING FUNDING FOR MICROBIOME RESEARCH TO SUPPORT MARKET GROWTH
TABLE 40 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.4.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE DEMAND FOR MICROBIOME-BASED PRODUCTS
TABLE 41 MICROBIOME-BASED DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 42 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
TABLE 43 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 US to account for largest share of during forecast period
TABLE 50 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 51 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 52 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 53 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 54 US: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 55 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 High prevalence of diseases in Canada to support market growth
TABLE 56 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 57 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 58 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 59 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 60 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 61 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
TABLE 62 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 66 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 68 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany to dominate European microbiome-based diagnostics market during forecast period
TABLE 69 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 70 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 71 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 72 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 73 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Growing number of microbiome sequencing start-ups to boost market growth
TABLE 75 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 76 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 77 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 78 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 79 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Supportive environment for microbiome sequencing R&D to support growth
TABLE 81 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 82 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 83 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 84 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 85 UK: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 87 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 88 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 89 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 90 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 91 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
TABLE 93 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Collaborations between academic institutes and private companies to drive growth
TABLE 100 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 101 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 103 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 104 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Rising aging population to drive market growth
TABLE 106 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 107 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 108 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 109 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 110 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing prevalence of diseases to drive market growth
TABLE 112 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 113 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 114 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 115 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 116 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 118 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 120 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 121 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 122 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 ASIA PACIFIC: RECESSION IMPACT
11.5 REST OF THE WORLD
TABLE 124 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 125 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 126 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 127 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 128 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 REST OF THE WORLD: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 130 OVERVIEW OF STRATEGIES ADOPTED BY KEY MICROBIOME-BASED DIAGNOSTIC MANUFACTURERS
12.3 REVENUE ANALYSIS
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS
12.4 MARKET SHARE ANALYSIS
TABLE 131 MICROBIOME-BASED DIAGNOSTICS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 31 MICROBIOME-BASED DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
12.5.5 COMPANY FOOTPRINT ANALYSIS
TABLE 132 COMPANY FOOTPRINT
TABLE 133 COMPANY PRODUCT FOOTPRINT
TABLE 134 COMPANY REGIONAL FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 32 MICROBIOME-BASED DIAGNOSTICS MARKET: START-UP/SME EVALUATION MATRIX, 2022
12.6.5 COMPETITIVE BENCHMARKING
TABLE 135 MICROBIOME-BASED DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.7 COMPETITIVE SCENARIO & TRENDS
12.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 136 MICROBIOME-BASED DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023
12.7.2 DEALS
TABLE 137 MICROBIOME-BASED DIAGNOSTICS MARKET: DEALS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 GENETIC ANALYSIS AS
TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW
FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022)
13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.)
TABLE 139 DNA GENOTEK: COMPANY OVERVIEW
FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
13.1.3 MICROBA LIFE SCIENCES
TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW
FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023)
13.1.4 ILLUMINA INC.
TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW
FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC
TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022)
13.1.6 BIOME OXFORD LTD.
TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW
13.1.7 VIENNALAB DIAGNOSTICS GMBH
TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW
13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.)
TABLE 145 METABIOMICS: COMPANY OVERVIEW
13.1.9 VIOME LIFE SCIENCES
TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW
13.1.10 LUXIA SCIENTIFIC
TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW
13.1.11 SUN GENOMICS
TABLE 148 SUN GENOMICS: COMPANY OVERVIEW
13.1.12 ATLAS BIOMED
TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW
13.1.13 QUANTBIOME, INC. (DBA OMBRE)
TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW
13.1.14 BECTON, DICKINSON AND COMPANY
TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
13.1.15 DAYTWO
TABLE 152 DAYTWO: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MICRONOMA
13.2.2 TERAOMICS S.L.
13.2.3 FLIGHTPATH BIOSCIENCES
13.2.4 MICROBIOME RESEARCH PVT. LTD.
13.2.5 ORIGIN SCIENCES
13.2.6 LEUCINE RICH BIO PRIVATE LIMITED
13.2.7 DECODE AGE
13.2.8 EVVY
13.2.9 ALPHABIOMICS, LTD.
13.2.10 GOODGUT
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
TABLE 1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
FIGURE 1 MICROBIOME-BASED DIAGNOSTICS MARKET SCOPE
1.3.1 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 MICROBIOME-BASED DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
2.1.2.3 Breakdown of primary interviews
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary research
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.2.2 TOP-DOWN APPROACH
FIGURE 8 MICROBIOME-BASED DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.3 DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 STUDY ASSUMPTIONS
2.5 RESEARCH LIMITATIONS AND RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: MICROBIOME-BASED DIAGNOSTICS MARKET
2.6 IMPACT OF RECESSION ON MICROBIOME-BASED DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY
FIGURE 10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
FIGURE 11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)
FIGURE 12 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2023 VS. 2028 (USD MILLION)
FIGURE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
FIGURE 14 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF MICROBIOME-BASED DIAGNOSTICS MARKET
4 PREMIUM INSIGHTS
4.1 MICROBIOME-BASED DIAGNOSTICS MARKET OVERVIEW
FIGURE 16 RISING DISEASE INCIDENCE AND TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT & COUNTRY (2022)
FIGURE 17 KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
4.3 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 18 CHINA AND INDIA TO WITNESS HIGHEST GROWTH RATES DURING FORECAST PERIOD
4.4 MICROBIOME-BASED DIAGNOSTICS MARKET: GEOGRAPHIC MIX
FIGURE 19 APAC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
4.5 MICROBIOME-BASED DIAGNOSTICS MARKET: DEVELOPED VS. EMERGING ECONOMIES
FIGURE 20 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 MICROBIOME-BASED DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing prevalence of chronic diseases
FIGURE 22 GLOBAL INCIDENCE OF DIABETES, 2021 VS. 2045
5.2.1.2 Collaborative efforts between microbiome industry and academia for microbiome research
5.2.1.3 Growing demand for personalized medicine
5.2.1.4 Rising awareness about importance of human microbiomes
5.2.1.5 Rising funding and investments in microbiome research
5.2.2 RESTRAINTS
5.2.2.1 End-user budget constraints in developing countries
5.2.3 OPPORTUNITIES
5.2.3.1 Increased collaboration between key players and small innovative companies to work on new microbiome technologies
TABLE 3 COLLABORATIONS IN MICROBIOME-BASED DIAGNOSTICS MARKET
5.2.4 CHALLENGES
5.2.4.1 Adverse impact of complex regulatory policies on commercialization of microbiome
5.3 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 INTENSITY OF COMPETITIVE RIVALRY
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 THREAT OF SUBSTITUTES
5.6 KEY STAKEHOLDERS & BUYING CRITERIA
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 2 END USERS
5.6.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS
5.7 REGULATORY LANDSCAPE
5.7.1 NORTH AMERICA
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 EUROPE
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.3 ASIA PACIFIC
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.4 REST OF THE WORLD
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 ECOSYSTEM ANALYSIS
TABLE 8 ROLE IN ECOSYSTEM
FIGURE 27 KEY PLAYERS OPERATING IN MICROBIOME-BASED DIAGNOSTICS MARKET
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES & EVENTS
TABLE 9 LIST OF CONFERENCES & EVENTS IN 2023–2024
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
TABLE 10 PRICE RANGE OF PRODUCTS OFFERED BY KEY PLAYERS FOR APPLICATIONS (USD)
5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.13 TECHNOLOGY ANALYSIS
5.13.1 DEVELOPMENT OF NOVEL MICROBIOME SAMPLING DEVICES
5.14 TRADE ANALYSIS
TABLE 11 IMPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 902780, BY COUNTRY, 2018–2021 (USD MILLION)
6 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
TABLE 13 MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
6.2 KITS & REAGENTS
6.2.1 KITS & REAGENTS TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
TABLE 14 MICROBIOME-BASED DIAGNOSTIC KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING VOLUME OF BLOOD COLLECTION PROCEDURES TO DRIVE MARKET GROWTH
TABLE 15 MICROBIOME-BASED DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
7 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
TABLE 16 MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
7.2 16S RRNA SEQUENCING
7.2.1 ABILITY TO COMBINE MANY SAMPLES IN SEQUENCING RUN TO DRIVE DEMAND FOR NGS-BASED 16S RRNA SEQUENCING
TABLE 17 MICROBIOME-BASED DIAGNOSTICS MARKET FOR 16S RRNA SEQUENCING, BY REGION, 2021–2028 (USD MILLION)
7.3 SHOTGUN METAGENOMICS
7.3.1 ABILITY OF SHOTGUN METAGENOMICS TO PROVIDE DETAILED GENETIC INFORMATION TO BOOST DEMAND
TABLE 18 COMPARISON BETWEEN SHOTGUN METAGENOMICS AND 16S RRNA SEQUENCING
TABLE 19 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SHOTGUN METAGENOMICS, BY REGION, 2021–2028 (USD MILLION)
7.4 METATRANSCRIPTOMICS
7.4.1 ONGOING TECHNOLOGICAL ADVANCEMENTS IN SEQUENCING INSTRUMENTS TO DRIVE GROWTH
TABLE 20 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METATRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION)
7.5 OTHER TECHNOLOGIES
TABLE 21 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2021–2028 (USD MILLION)
8 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE
8.1 INTRODUCTION
TABLE 22 MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
8.2 FECAL SAMPLES
8.2.1 FECAL SAMPLES TO DOMINATE MICROBIOME-BASED DIAGNOSTICS MARKET DURING FORECAST PERIOD
TABLE 23 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR FECAL SAMPLES
TABLE 24 MICROBIOME-BASED DIAGNOSTICS MARKET FOR FECAL SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.3 SALIVA SAMPLES
8.3.1 ADVANCEMENTS IN ORAL DIAGNOSTICS TO DRIVE MARKET GROWTH
TABLE 25 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SALIVA SAMPLES
TABLE 26 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SALIVA SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.4 SKIN SAMPLES
8.4.1 GROWING FOCUS ON MICROBIOME RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 27 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR SKIN SAMPLES
TABLE 28 MICROBIOME-BASED DIAGNOSTICS MARKET FOR SKIN SAMPLES, BY REGION, 2021–2028 (USD MILLION)
8.5 OTHER SAMPLES
TABLE 29 LIST OF MICROBIOME-BASED DIAGNOSTIC KITS FOR OTHER SAMPLES
TABLE 30 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2021–2028 (USD MILLION)
9 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION
9.1 INTRODUCTION
TABLE 31 MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
9.2 DISEASE DIAGNOSTIC APPLICATIONS
TABLE 32 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 33 MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9.2.1 GASTROINTESTINAL DISORDERS
9.2.1.1 Growing incidence of gastrointestinal disorders to drive market growth
TABLE 34 MICROBIOME-BASED DIAGNOSTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.2.2 METABOLIC DISORDERS
9.2.2.1 High prevalence of metabolic disorders to drive demand for microbiome-based diagnostic products
TABLE 35 MICROBIOME-BASED DIAGNOSTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2021–2028 (USD MILLION)
9.2.3 OTHER DISEASE DIAGNOSTIC APPLICATIONS
TABLE 36 MICROBIOME-BASED DIAGNOSTICS MARKET FOR OTHER DISEASE DIAGNOSTIC APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
9.3 RESEARCH APPLICATIONS
9.3.1 GROWING RESEARCH ACTIVITIES TO BOOST MARKET
TABLE 37 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
10 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
TABLE 38 MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
10.2 HOSPITALS
10.2.1 HOSPITALS ACCOUNTED FOR LARGEST SHARE OF MICROBIOME-BASED DIAGNOSTICS MARKET IN 2022
TABLE 39 MICROBIOME-BASED DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021–2028 (USD MILLION)
10.3 RESEARCH INSTITUTES
10.3.1 GROWING FUNDING FOR MICROBIOME RESEARCH TO SUPPORT MARKET GROWTH
TABLE 40 MICROBIOME-BASED DIAGNOSTICS MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
10.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.4.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE DEMAND FOR MICROBIOME-BASED PRODUCTS
TABLE 41 MICROBIOME-BASED DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
11 MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
TABLE 42 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY REGION, 2021–2028 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
TABLE 43 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 44 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 45 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 46 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 47 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 48 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 49 NORTH AMERICA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.1 US
11.2.1.1 US to account for largest share of during forecast period
TABLE 50 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 51 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 52 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 53 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 54 US: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 55 US: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.2 CANADA
11.2.2.1 High prevalence of diseases in Canada to support market growth
TABLE 56 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 57 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 58 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 59 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 60 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 61 CANADA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.2.3 NORTH AMERICA: RECESSION IMPACT
11.3 EUROPE
TABLE 62 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 63 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 64 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 65 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 66 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 67 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 68 EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Germany to dominate European microbiome-based diagnostics market during forecast period
TABLE 69 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 70 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 71 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 72 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 73 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 74 GERMANY: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.2 FRANCE
11.3.2.1 Growing number of microbiome sequencing start-ups to boost market growth
TABLE 75 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 76 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 77 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 78 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 79 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 80 FRANCE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.3 UK
11.3.3.1 Supportive environment for microbiome sequencing R&D to support growth
TABLE 81 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 82 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 83 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 84 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 85 UK: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 86 UK: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.4 REST OF EUROPE
TABLE 87 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 88 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 89 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 90 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 91 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 92 REST OF EUROPE: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.3.5 EUROPE: RECESSION IMPACT
11.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET SNAPSHOT
TABLE 93 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
TABLE 94 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 95 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 96 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 97 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 98 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 99 ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Collaborations between academic institutes and private companies to drive growth
TABLE 100 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 101 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 102 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 103 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 104 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 105 CHINA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Rising aging population to drive market growth
TABLE 106 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 107 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 108 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 109 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 110 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 111 JAPAN: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing prevalence of diseases to drive market growth
TABLE 112 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 113 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 114 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 115 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 116 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 117 INDIA: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 118 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 119 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 120 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 121 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 122 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 123 REST OF ASIA PACIFIC: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.4.5 ASIA PACIFIC: RECESSION IMPACT
11.5 REST OF THE WORLD
TABLE 124 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
TABLE 125 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION)
TABLE 126 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY SAMPLE, 2021–2028 (USD MILLION)
TABLE 127 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
TABLE 128 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET FOR DISEASE DIAGNOSTIC APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)
TABLE 129 REST OF THE WORLD: MICROBIOME-BASED DIAGNOSTICS MARKET, BY END USER, 2021–2028 (USD MILLION)
11.5.1 REST OF THE WORLD: RECESSION IMPACT
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 130 OVERVIEW OF STRATEGIES ADOPTED BY KEY MICROBIOME-BASED DIAGNOSTIC MANUFACTURERS
12.3 REVENUE ANALYSIS
FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS
12.4 MARKET SHARE ANALYSIS
TABLE 131 MICROBIOME-BASED DIAGNOSTICS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION MATRIX
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
FIGURE 31 MICROBIOME-BASED DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
12.5.5 COMPANY FOOTPRINT ANALYSIS
TABLE 132 COMPANY FOOTPRINT
TABLE 133 COMPANY PRODUCT FOOTPRINT
TABLE 134 COMPANY REGIONAL FOOTPRINT
12.6 START-UP/SME EVALUATION MATRIX
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
FIGURE 32 MICROBIOME-BASED DIAGNOSTICS MARKET: START-UP/SME EVALUATION MATRIX, 2022
12.6.5 COMPETITIVE BENCHMARKING
TABLE 135 MICROBIOME-BASED DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.7 COMPETITIVE SCENARIO & TRENDS
12.7.1 PRODUCT LAUNCHES & APPROVALS
TABLE 136 MICROBIOME-BASED DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, 2020–2023
12.7.2 DEALS
TABLE 137 MICROBIOME-BASED DIAGNOSTICS MARKET: DEALS, 2020–2023
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 GENETIC ANALYSIS AS
TABLE 138 GENETIC ANALYSIS AS: COMPANY OVERVIEW
FIGURE 33 GENETIC ANALYSIS AS: COMPANY SNAPSHOT (2022)
13.1.2 DNA GENOTEK (ORASURE TECHNOLOGIES, INC.)
TABLE 139 DNA GENOTEK: COMPANY OVERVIEW
FIGURE 34 ORASURE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
13.1.3 MICROBA LIFE SCIENCES
TABLE 140 MICROBA LIFE SCIENCES: COMPANY OVERVIEW
FIGURE 35 MICROBA LIFE SCIENCES: COMPANY SNAPSHOT (2023)
13.1.4 ILLUMINA INC.
TABLE 141 ILLUMINA INC.: COMPANY OVERVIEW
FIGURE 36 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
13.1.5 OXFORD NANOPORE TECHNOLOGIES, PLC
TABLE 142 OXFORD NANOPORE TECHNOLOGIES, PLC: COMPANY OVERVIEW
FIGURE 37 OXFORD NANOPORE TECHNOLOGIES, PLC.: COMPANY SNAPSHOT (2022)
13.1.6 BIOME OXFORD LTD.
TABLE 143 BIOME OXFORD LTD.: COMPANY OVERVIEW
13.1.7 VIENNALAB DIAGNOSTICS GMBH
TABLE 144 VIENNALAB DIAGNOSTICS GMBH: COMPANY OVERVIEW
13.1.8 METABIOMICS (A SUBSIDIARY OF PRESCIENT MEDICINE HOLDINGS, INC.)
TABLE 145 METABIOMICS: COMPANY OVERVIEW
13.1.9 VIOME LIFE SCIENCES
TABLE 146 VIOME LIFE SCIENCES: COMPANY OVERVIEW
13.1.10 LUXIA SCIENTIFIC
TABLE 147 LUXIA SCIENTIFIC: COMPANY OVERVIEW
13.1.11 SUN GENOMICS
TABLE 148 SUN GENOMICS: COMPANY OVERVIEW
13.1.12 ATLAS BIOMED
TABLE 149 ATLAS BIOMED: COMPANY OVERVIEW
13.1.13 QUANTBIOME, INC. (DBA OMBRE)
TABLE 150 QUANTBIOME, INC.: COMPANY OVERVIEW
13.1.14 BECTON, DICKINSON AND COMPANY
TABLE 151 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
13.1.15 DAYTWO
TABLE 152 DAYTWO: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS
13.2.1 MICRONOMA
13.2.2 TERAOMICS S.L.
13.2.3 FLIGHTPATH BIOSCIENCES
13.2.4 MICROBIOME RESEARCH PVT. LTD.
13.2.5 ORIGIN SCIENCES
13.2.6 LEUCINE RICH BIO PRIVATE LIMITED
13.2.7 DECODE AGE
13.2.8 EVVY
13.2.9 ALPHABIOMICS, LTD.
13.2.10 GOODGUT
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
